Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Researchers develop new serological assay for detection of SARS-CoV-2 antibodies

Researchers at UC Santa Cruz have developed a novel serological assay for the detection of antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.

10 Dec 2020

EKF launches high performance quantitative COVID-SeroKlir antibody test kit

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.

From EKF Diagnostics 10 Dec 2020

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

A recent study by US researchers, currently available on the medRxiv preprint server, evaluated several cell-based assays that are under validation for determining correlates of protection in individuals with symptomatic coronavirus disease (COVID-19) and vaccine studies – and demonstrated their high concordance with both live and pseudotyped virions.

9 Dec 2020

Evolutionary gene mutation unique to humans may be to blame for risk of advanced cancers

Compared to chimpanzees, our closest evolutionary cousins, humans are particularly prone to developing advanced carcinomas -- the type of tumors that include prostate, breast, lung and colorectal cancers -- even in the absence of known risk factors, such as genetic predisposition or tobacco use.

9 Dec 2020

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalizations or severe disease reported in the COVID-19 vaccine group so far.

9 Dec 2020

Researchers compare data from blood donors to infer the attack rate of SARS-CoV-2 virus

Researchers studying data from blood donors in Manaus, Brazil, who experienced high mortality from SARS-CoV-2, estimate that more than 70% of the population was infected approximately seven months after the virus first arrived in the city.

9 Dec 2020

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

A new study published on the preprint server bioRxiv in December 2020 indicates the ability of anti-SARS-CoV-2 antibody titers and time of induction to differentiate between severe and mild COVID-19 and could lead to the development of a prognostic biomarker for use early in the course of the illness.

8 Dec 2020

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Early study data shows a 29% overall response rate, the favorable safety profile in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

8 Dec 2020

UCI researchers develop new technology to rapidly hypermutate antibodies

Using the same strain of yeast that ferments wine and makes dough rise, a team led by University of California, Irvine and Harvard Medical School researchers has developed an in vitro technology that can rapidly hypermutate antibodies.

8 Dec 2020

Researchers address variability of disease severity in respiratory tract infections

Is it possible to predict the course of a viral respiratory tract infection - for instance one caused by a coronavirus - based on individual patient characteristics? This question will be addressed by Dr. Victor Corman and his junior research group at Charité - Universitätsmedizin Berlin.

8 Dec 2020

Studies show IgA antibodies dominate early response to SARS-CoV-2 virus

A new study of more than 150 COVID-19 patients shows that IgA antibodies dominate the early response to the SARS-CoV-2 virus, coming on more quickly and strongly than IgG and IgM antibodies. This is a somewhat unexpected result, as IgM antibodies are usually the immune system's first responders.

7 Dec 2020

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Antibody responses to SARS-CoV-2 virus disappear quickly during convalescence, indicates study

A new 5-month longitudinal analysis of 254 COVID-19 patients who displayed a wide range of disease severity - from asymptomatic to deadly illness - suggests that IgA and IgM antibodies to the SARS-CoV-2 virus disappear quickly during convalescence.

7 Dec 2020

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Primary central nervous system lymphoma (PCNSL) is a type of cancer that develops in the brain and or spinal cord.

7 Dec 2020

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

The intranasal route of immunization may offer effective protection against SARS-CoV-2

Researchers at the School of Medicine, Washington University in Saint Louis, USA, showed that the intranasal route of immunization could provide a more efficient protection against SARS-CoV-2 compared to the intramuscular route (i.e. through ‘jabs’).

7 Dec 2020

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

In a new study, researchers describe the identification of a neutralizing antibody that binds to the RBD at the same site as the human host cell receptor.

7 Dec 2020

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

A new study describes an ELISA assay that combines the detection of IgM, IgA, and IgG antibodies against the SARS−CoV−2 trimeric spike glycoprotein.

7 Dec 2020

Novel modular design approach to antibody nanocage generation

A new study shows the benefits of using computational design to create antibody nanocages that have the required orientation.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Antibody News and Research

Further Reading

Researchers develop new serological assay for detection of SARS-CoV-2 antibodies

EKF launches high performance quantitative COVID-SeroKlir antibody test kit

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

Evolutionary gene mutation unique to humans may be to blame for risk of advanced cancers

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

Researchers compare data from blood donors to infer the attack rate of SARS-CoV-2 virus

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

UCI researchers develop new technology to rapidly hypermutate antibodies

Researchers address variability of disease severity in respiratory tract infections

Studies show IgA antibodies dominate early response to SARS-CoV-2 virus

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Antibody responses to SARS-CoV-2 virus disappear quickly during convalescence, indicates study

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

The intranasal route of immunization may offer effective protection against SARS-CoV-2

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

Novel modular design approach to antibody nanocage generation

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo